Jupiter Neurosciences Defers $6M Convertible Note Repayments to April 2026
Jupiter Neurosciences deferred repayment commencement on its $6.0 million convertible notes to April 1, 2026, with principal now following an agreed schedule while core economic terms remain unchanged. The amendment aligns financing with its Phase II Parkinson’s trial and Nugevia™ commercial rollout, preserving liquidity for clinical and revenue-generating operations.
1. Amendment Details
Jupiter Neurosciences entered an omnibus amendment with YA II PN, Ltd. to defer monthly installment payments on its $6.0 million convertible promissory notes until April 1, 2026, with principal repayments now following a mutually agreed schedule; the amendment introduces no new pricing, maturity changes or additional financing commitments.
2. Financing Impact and Runway
By preserving the original economic terms and shifting installment timing, the amendment aligns the company’s capital structure with its operational milestones, bolsters its cash runway for clinical activities and commercial initiatives, and reinforces alignment with its financing partner.
3. Clinical and Commercial Strategy
Jupiter’s dual-path strategy combines a Phase IIa Parkinson’s disease trial with Nugevia™ ecommerce sales, which currently show a 25% repeat purchase rate and a 3% return rate, providing early commercial validation and supplementary cash flow alongside clinical development.